USD10
AUPH Anteile
Über Aurinia PharmaceuticalsAurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
USD10
AUPH Anteile
Über Aurinia PharmaceuticalsAurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Statistiken
TRADINGFENSTER
Geschlossen
ÖFFNET AM
23. März at 13:30 GMT+0
MARKTKAPITALISIERUNG
1,95 Mrd. $
ERÖFFNUNGSPREIS
14,37 $
TIEF (1 J)
6,55 $
HOCH (1 J)
16,54 $
TIEF (24 STD.)
14,36 $
HOCH (24 STD.)
15,22 $
VOLUMEN (24 STD.)
2,65 Mio. $
110,3 %
Kursverlauf
Time | Price | Change |
|---|---|---|
Heute | 14,37 $ | |
1 Tag | 13,99 $ | |
1 Woche | 14,49 $ | |
1 Monat | 14,70 $ | |
1 Jahr | 8,53 $ |